SpotitEarly BRCA is a molecular test used to identify patients with germline BRCA1/2 mutations. The test aims to identify 3 inherited mutations in BRCA 1 and 2, common among Ashkenazi Jews, and known to cause breast and ovarian cancer with high prevalence. This method is well established and widely used for population screening by healthcare providers and hospitals in Israel, and by Jewish communities worldwide. Breast cancer professional guideline updates recommend germline testing for all breast cancer patients. The results of each test component, along with the interpretation of variant(s) identified, will be delivered within 2 weeks.